Anas Gazzah

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Christophe Massard, Stefan Michiels, Charles Ferté et al. · Cancer Discovery · 2017 · 747 citations

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Roberto Ferrara, Laura Mezquita, Matthieu Texier et al. · JAMA Oncology · 2018 · 719 citations · Full text

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann et al. · Journal of Clinical Oncology · 2015 · 371 citations

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

Mélodie Tazdait, Laura Mezquita, J. Lahmar et al. · European Journal of Cancer · 2017 · 337 citations

Oncology, Medicine, Recist 1.1 +6

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg et al. · Nature Medicine · 2023 · 252 citations · Full text